Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable). Immunotherapy with atezolizumab, may include changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rак gardła związany z HPV (stadium I)
- •Nowotwór można usunąć chirurgicznie
- •Brak rozleglych zmian chorobowych na obrazach przed operacją
- •Kobiety w wieku rozrodczym muszą stosować antykoncepcję przez czas badania i 5 miesięcy po leku
- •Mężczyźni muszą stosować antykoncepcję przez czas badania i 3 miesiące po leku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Emory University Hospital Midtown
Atlanta, United States
Trial contact
Nabil F. Saba, MD, FACP
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.